Alebund Pharmaceuticals Raises $54.5 Million In Series B+ Financing Round To Fuel Development Of Renal Disease Treatment
Amount Raised
$54.5 Million
Round Type
Series B
ShanghaiBiotechnologyHealth CarePharmaceuticalDescription
Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has secured $54.5 million in its Series B+ financing round. This round was led by 3H Health Investment, Loyal Valley Capital and Morningside Ventures, followed by YuanBio Venture Capital, Octagon Capital, Verition Fund Management and HT Capital. Existing Shareholders including Lilly Asia Ventures, Quan Capital, a prominent sovereign wealth fund, 3E Bioventures Capital and Sherpa Healthcare Partners also took part in the financing. Proceeds raised in this round will help accelerate the development of Alebund's clinical programs, the construction of the manufacturing site, the research of pre-clinical assets, and the expansion of Company's talent pool.
Quick answer
Alebund Pharmaceutical raised $54.5 Million in a Series B round, dated September 14, 2021. Alebund Pharmaceutical is based in Shanghai, Shanghai, China.
- How much did Alebund Pharmaceutical raise?
- Alebund Pharmaceutical raised $54.5 Million in a Series B round on September 14, 2021.
- What does Alebund Pharmaceutical do?
- Alebund was incubated in Shanghai in 2018.
- Where is Alebund Pharmaceutical based and how big is it?
- Alebund Pharmaceutical is based in Shanghai, Shanghai, China. Fundz records about 3 employees.
- Who are the decision-makers at Alebund Pharmaceutical?
- Fundz holds 1 contact at Alebund Pharmaceutical. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Pharmaceutical and Biotechnology around the same time
Companies in the same sectors as Alebund Pharmaceutical that raised within 45 days of this round, from Fundz verified event records.
- INNOCAN PHARMA Corp raised $6.6M on October 26, 2021.
- Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raised an undisclosed amount (Debt Financing) on October 18, 2021.
- Cingulate raised an undisclosed amount on September 28, 2021.
- Journey Medical Corporation raised $19M on September 22, 2021.
- Newron Pharmaceuticals S.p.A. & EA Pharma Ltd raised an undisclosed amount (Debt Financing) on September 6, 2021.
- Disc raised $90M (Series B) on September 2, 2021.
Who to call at Alebund Pharmaceutical, and when
A new round usually means Alebund Pharmaceutical is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alebund Pharmaceutical raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alebund Pharmaceutical, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alebund Pharmaceutical. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alebund Pharmaceutical raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAlebund Pharmaceutical raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.